No label defined (Q2867043)

From EU Knowledge Graph
Revision as of 01:11, 7 July 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): PNmAb aims to create an innovative antibacterial antibacterial therapy directed against five of the bacteria most harmful to public health. This therapy is based on the discovery of a mechanism of virulence that is common to these bacteria and that results from years of research., translated_summary)
Jump to navigation Jump to search
Project Q2867043 in Portugal
Language Label Description Also known as
English
No label defined
Project Q2867043 in Portugal

    Statements

    0 references
    936,601.26 Euro
    0 references
    76.0 percent
    0 references
    1 November 2019
    0 references
    31 October 2021
    0 references
    IMMUNETHEP, S.A.
    0 references

    40°21'55.76"N, 8°39'29.95"W
    0 references
    O PNmAb visa a criação de uma terapêutica antibacteriana inovadora à base de anticorpos direcionada contra cinco das bactérias mais nocivas para a saúde pública. Esta terapia está assente na descoberta de um mecanismo de virulência que é comum a estas bactérias e que resulta de anos de investigação. (Portuguese)
    0 references
    PNmAb aims to create an innovative antibacterial antibacterial therapy directed against five of the bacteria most harmful to public health. This therapy is based on the discovery of a mechanism of virulence that is common to these bacteria and that results from years of research. (English)
    7 July 2021
    0 references
    Cantanhede
    0 references

    Identifiers

    CENTRO-01-0247-FEDER-045262
    0 references